December 22, 2020
Beyeonics Surgical announced Dr. Sharon Bakalash was appointed chief medical officer effective October 1, 2020.
Beyeonics Surgical notes Dr. Sharon Bakalsh is a seasoned biotechnology entrepreneur and an ophthalmic surgeon with more than two decades of demonstrated leadership in business, science, and medicine. Before stepping in as Beyeonics Surgical CMO, she had worked with the company as a consultant for nearly 4 years.
As the founder of SB Strategic Development Consultants Group, she provided clinical development, strategic planning, and business development guidance to Beyeonics, as well as with other start-up companies, venture funds and global pharma companies- spanning the pharmaceutical, drug delivery and surgical device arenas.
Dr. Bakalash had served in various roles of exceeding responsibilities within the pharmaceutical industry. In her last role within Novartis, she was responsible for the US early development portfolio in both Ophthalmology and ENT—forming development strategies, enabling pipeline enrichment stemming for both external and internal innovation. Prior to that, she headed business development at Alcon, where she was evaluated, negotiated, and oversaw numerous transactions- spanning acquisitions, joint ventures, and a wide variety of co- development frameworks.
Prior to Novartis, Dr. Bakalash was a part of the Harvard University Office of Technology Development, out-licensing innovations stemming from the medical school.
Dr. Bakalash holds an MD from Ben Gurion University, a PhD in Neuroimmunology from the Weizmann Institute of Science, and a business degree from Northeastern University. Dr. Bakalash has also completed a post-doctoral fellowship at Harvard University.